1. Switching from donepezil tablets to rivastigmine transdermal patch in Alzheimer's disease
- Author
-
Carl H, Sadowsky, Alan, Dengiz, Jason T, Olin, Barbara, Koumaras, Xiangyi, Meng, Stephen, Brannan, and Jaron, Winston
- Subjects
Male ,Time Factors ,Transdermal patch ,Phenylcarbamates ,Appetite ,Rivastigmine ,Administration, Cutaneous ,Drug Administration Schedule ,law.invention ,Electrocardiography ,Randomized controlled trial ,Piperidines ,law ,Alzheimer Disease ,medicine ,Humans ,In patient ,Donepezil ,Prospective Studies ,Aged ,business.industry ,General Neuroscience ,Nausea ,Psychiatry and Mental health ,Clinical Psychology ,Multicenter study ,Tolerability ,Anesthesia ,Indans ,Female ,Cholinesterase Inhibitors ,Geriatrics and Gerontology ,business ,Constipation ,medicine.drug - Abstract
Objective: Evaluate safety and tolerability of switching from donepezil to rivastigmine transdermal patch in patients with mild to moderate Alzheimer's disease. Methods: Prospective, parallel-group, open-label study to evaluate immediate or delayed switch from 5-10 mg/day donepezil to 4.6 mg/24 h rivastigmine following a 4-week treatment period. Results: Rates of discontinuation due to any reason or adverse events were similar between groups. Incidences of gastrointestinal adverse events were 3.8% in the immediate and 0.8% in the delayed switch group. No patients discontinued secondary to nausea and vomiting. Discontinuations due to application site reactions were low (2.3%). Asymptomatic bradycardia was more common following the immediate switch (2.3% vs 0%); however, these patients had coexisting cardiac comorbidities. Conclusion: Both switch strategies were safe and well tolerated. The majority of patients may be able to switch directly to rivastigmine patches without a withdrawal period. Appropriate clinical judgment should be used for patients with existing bradycardia or receiving β blockers.
- Published
- 2009